Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Marksans Pharma Limited (MARKSANS.NS)
Mumbai, IN
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +15.68% | +15.82% | +33.95% | +44.10% | +33.18% | +41.32% | +1.18% | +242.92% | +236.80% | +444.42% | +10,516.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+12.5% ★ Q1'26: +20.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+9.8% Q1'26: +63.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+9.4% ★ Q1'26: +0.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+17.1% Q1'26: +20.0% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+15.7% ★ Q1'26: +21.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.57× ★ Q1'26: 0.44× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 3 Rev. Ana. 3 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
Mar 2029 2 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.97B
est: 8.31B (-4.1%)
|
8.93B
est: 9.33B (-4.3%)
|
7.67B
est: 7.94B (-3.4%)
|
9.13B
est: 9.52B (-4.1%)
|
9.87B
est: 10.89B (-9.4%)
|
11.29B
est: 13.16B (-14.2%)
|
14.80B
est: 14.64B (+1.1%)
|
18.52B
est: 16.18B (+14.5%)
|
21.77B
est: 22.68B (-4.0%)
|
26.23B
est: 26.12B (+0.4%)
|
29.06B
28.92B – 29.18B
+11.3% YoY
|
33.76B
33.42B – 34.06B
+16.1% YoY
|
38.51B
38.49B – 38.53B
+14.1% YoY
|
50.44B
49.94B – 50.90B
+31.0% YoY
|
58.20B
57.62B – 58.73B
+15.4% YoY
|
| EBITDA |
1.76B
est: 1.84B (-4.4%)
|
1.45B
est: 1.92B (-24.4%)
|
329.19M
est: 1.19B (-72.3%)
|
868.57M
est: 671.89M (+29.3%)
|
1.33B
est: 761.68M (+74.7%)
|
1.93B
est: 2.91B (-33.7%)
|
3.01B
est: 3.24B (-7.2%)
|
3.99B
est: 3.58B (+11.3%)
|
5.09B
est: 5.02B (+1.4%)
|
5.29B
est: 5.78B (-8.6%)
|
6.43B
6.40B – 6.46B
+11.3% YoY
|
7.47B
7.40B – 7.54B
+16.1% YoY
|
8.52B
8.52B – 8.53B
+14.1% YoY
|
11.17B
11.05B – 11.27B
+31.0% YoY
|
12.88B
12.75B – 13.00B
+15.4% YoY
|
| EBIT |
1.65B
est: 1.59B (+3.6%)
|
1.13B
est: 1.80B (-37.2%)
|
188.59M
est: 908.22M (-79.2%)
|
562.92M
est: 33.10M (+1,600.6%)
|
1.10B
est: 526.83M (+109.2%)
|
1.62B
est: 2.51B (-35.4%)
|
2.56B
est: 2.80B (-8.6%)
|
3.47B
est: 3.09B (+12.1%)
|
4.35B
est: 4.34B (+0.2%)
|
4.45B
est: 4.99B (-10.9%)
|
5.56B
5.53B – 5.58B
+11.3% YoY
|
6.46B
6.39B – 6.51B
+16.1% YoY
|
7.37B
7.36B – 7.37B
+14.1% YoY
|
9.65B
9.55B – 9.73B
+31.0% YoY
|
11.13B
11.02B – 11.23B
+15.4% YoY
|
| Net Income |
1.09B
est: 1.30B (-16.2%)
|
785.12M
est: 1.23B (-36.4%)
|
95.19M
est: 683.72M (-86.1%)
|
329.40M
est: 103.52M (+218.2%)
|
804.37M
est: 336.32M (+139.2%)
|
1.21B
est: 780.67M (+54.7%)
|
1.85B
est: 2.40B (-23.1%)
|
2.66B
est: 2.81B (-5.2%)
|
3.14B
est: 3.34B (-6.0%)
|
3.81B
est: 3.76B (+1.3%)
|
3.87B
3.84B – 3.89B
+2.9% YoY
|
4.99B
4.69B – 5.37B
+28.9% YoY
|
5.86B
5.25B – 6.23B
+17.5% YoY
|
8.20B
8.09B – 8.30B
+40.0% YoY
|
9.24B
9.12B – 9.35B
+12.7% YoY
|
| SGA |
757.77M
est: 930.35M (-18.6%)
|
313.67M
est: 1.64B (-80.9%)
|
428.82M
est: 1.85B (-76.8%)
|
682.20M
est: 2.79B (-75.6%)
|
898.35M
est: 2.66B (-66.2%)
|
972.25M
est: 3.09B (-68.6%)
|
2.25B
est: 1.64B (+37.3%)
|
1.49B
est: 1.81B (-17.5%)
|
1.45B
est: 2.54B (-42.9%)
|
2.81B
est: 2.92B (-3.8%)
|
3.25B
3.24B – 3.27B
+11.3% YoY
|
3.78B
3.74B – 3.81B
+16.1% YoY
|
4.31B
4.31B – 4.31B
+14.1% YoY
|
5.65B
5.59B – 5.70B
+31.0% YoY
|
6.52B
6.45B – 6.57B
+15.4% YoY
|
| EPS |
2.67
est: 2.88 (-7.3%)
|
1.92
est: 2.75 (-30.2%)
|
0.22
est: 0.40 (-45.0%)
|
0.80
est: 1.30 (-38.5%)
|
1.97
est: 1.20 (+64.2%)
|
2.86
est: 1.70 (+68.2%)
|
4.51
est: 5.30 (-14.9%)
|
6.41
est: 6.20 (+3.4%)
|
6.92
est: 7.36 (-6.0%)
|
8.40
est: 8.30 (+1.2%)
|
8.55
8.48 – 8.58
+3.0% YoY
|
11.05
10.35 – 11.85
+29.2% YoY
|
12.80
11.58 – 13.76
+15.8% YoY
|
18.10
17.87 – 18.31
+41.4% YoY
|
20.40
20.14 – 20.64
+12.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 2.07M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 68.0K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 153.5K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 7.57M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 92.8K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 8.00M | 0.05% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 12.2K | 0.22% |
| 8 | Vanguard Total World Stock ETF VT | 0.00% | 396.9K | 0.06% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 36.7K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 19.7K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark Saldanha | Non-Independent Executive Chairman & MD | 64M | male |
| Sandra Saldanha | Whole-Time Executive Non Independent Director | 24M | female |
| Varddhman Vikramaditya Jain | Whole-Time Executive Non Independent Director | 24M | male |
| Jitendra Sharma | Group Chief Financial Officer | — | male |
| Sathish Kumar | Managing Director of UK Operations | — | male |
| Sunil K. Rane | Senior Vice President of QC | — | male |
| Anjani Kumar | Chief Operating Officer of US Operations | — | male |
| Vishal Bhargava | Director Operations | — | male |
| David Mohammed | Managing Director of Australia Operations | — | male |
| Harshavardhan Panigrahi | Company Secretary, Manager of Legal & Compliance Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MARKSANS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
